The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer
2008
Development of INT131 as a Selective PPARγ Modulator for Diabetes Treatment
publication
Evidence: moderate
Author Information
Author(s): Linda S. Higgins, Christos S. Mantzoros
Primary Institution: InteKrin Therapeutics, Inc.
Hypothesis
Can selective modulation of PPARγ create a safer insulin sensitizer for type-2 diabetes?
Conclusion
INT131 shows potential as a potent insulin-sensitizing drug with minimal side effects compared to traditional treatments.
Supporting Evidence
- INT131 was designed to minimize side effects while maintaining efficacy.
- INT131 showed a significant reduction in fasting plasma glucose in early studies.
- INT131 demonstrated a high level of efficacy in reducing glucose and insulin levels.
Takeaway
INT131 is a new medicine that helps people with diabetes without causing weight gain or other bad side effects.
Methodology
The study involved preclinical models and early clinical trials to assess the efficacy and safety of INT131.
Limitations
No advanced clinical development reports for SPPARMs have been published yet.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website